Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2023-10-13 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-10-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It provides an update on the company's expected financial results for the third quarter of 2023, specifically discussing an acquired in-process research and development charge and its impact on GAAP and non-GAAP net income per diluted share. The document does not contain full financial statements or comprehensive financial analysis but rather a specific financial update and explanation of a particular charge affecting quarterly results. This type of filing is typically categorized as a Regulatory Filing (RNS) because it is a current report providing material information outside of regular periodic reports like 10-K or 10-Q, and it is not a full earnings release or interim report. The document also includes forward-looking statements and non-GAAP financial measure explanations, common in SEC current reports. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-10-05 English
PRIMARY DOCUMENT
Director's Dealing
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings
2023-10-02 English
SC 13D/A
Major Shareholding Notification
2023-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.